SEC Filing Summary: ChromaDex Corporation (8-K)
Business Context and Reporting Period
This Form 8-K was filed by ChromaDex Corporation on August 14, 2017, reporting events occurring on August 10, 2017. The filing details the results of a Special Meeting of Stockholders held to approve a financing transaction involving the issuance of common stock. Note: The input metadata references "Niagen Bioscience, Inc.," but the filing text explicitly identifies the registrant as ChromaDex Corporation.
Key Financial Metrics
This filing is a current report regarding corporate governance and does not contain financial performance data. The text does not provide values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes and Voting Results
Stockholders approved the issuance of common stock in connection with a financing transaction. The voting breakdown for the proposal was as follows:
- Shares Outstanding (Record Date June 19, 2017): 46,093,894
- Shares Present/Represented: 25,012,872
- Votes For: 24,779,564
- Votes Against: 223,926
- Abstentions: 9,382
- Broker Non-Votes: 0
Shares held by the transaction purchasers, Champion River Ventures Limited and Pioneer Step Holdings Limited, were excluded from voting pursuant to NASDAQ listing rules.
Guidance, Outlook, and Risks
The filing does not contain management commentary, financial guidance, or specific risk factors beyond the standard disclosure of the financing transaction approval. No unusual items or contingencies were detailed in this specific report.
Investor Verification Checklist
- Verify the terms of the financing transaction approved by stockholders, as the specific deal mechanics are not detailed in this 8-K.
- Confirm the identity of the registrant (ChromaDex Corporation) versus the metadata reference (Niagen Bioscience, Inc.).
- Review subsequent filings for the actual issuance of shares and capital raised from the approved transaction.
- Check for any related proxy statements or press releases from August 2017 for detailed financial impact analysis.